ZA200408571B - Composition for stimulating de novo bone induction - Google Patents
Composition for stimulating de novo bone induction Download PDFInfo
- Publication number
- ZA200408571B ZA200408571B ZA2004/08571A ZA200408571A ZA200408571B ZA 200408571 B ZA200408571 B ZA 200408571B ZA 2004/08571 A ZA2004/08571 A ZA 2004/08571A ZA 200408571 A ZA200408571 A ZA 200408571A ZA 200408571 B ZA200408571 B ZA 200408571B
- Authority
- ZA
- South Africa
- Prior art keywords
- bone
- composition
- novo
- trauma
- stimulating
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims description 89
- 230000006698 induction Effects 0.000 title claims description 37
- 239000000203 mixture Substances 0.000 title claims description 36
- 230000004936 stimulating effect Effects 0.000 title claims description 22
- 210000002469 basement membrane Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 25
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 24
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 24
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 23
- 208000014674 injury Diseases 0.000 claims description 23
- 230000008733 trauma Effects 0.000 claims description 23
- 230000002188 osteogenic effect Effects 0.000 claims description 22
- 230000003412 degenerative effect Effects 0.000 claims description 21
- 208000020084 Bone disease Diseases 0.000 claims description 19
- 108010082117 matrigel Proteins 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 13
- 206010065687 Bone loss Diseases 0.000 claims description 10
- 230000009466 transformation Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 241000288906 Primates Species 0.000 claims description 6
- 230000007547 defect Effects 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 231100001055 skeletal defect Toxicity 0.000 claims description 5
- 108010042086 Collagen Type IV Proteins 0.000 claims description 4
- 102000004266 Collagen Type IV Human genes 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- 108010085895 Laminin Proteins 0.000 claims description 4
- 108010067787 Proteoglycans Proteins 0.000 claims description 4
- 230000014616 translation Effects 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 210000002744 extracellular matrix Anatomy 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 101710167839 Morphogenetic protein Proteins 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 2
- 235000004252 protein component Nutrition 0.000 claims 1
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000011164 ossification Effects 0.000 description 9
- 241001504519 Papio ursinus Species 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011670 long-evans rat Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 206010058112 Chondrolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
K
COMPOSITION FOR STIMULATING DE NOVO BONE INDUCTION
This invention relates to a composition for initiating de novo bone induction, to a delivery system for initiating de novo bone induction and to a method of treating a : mammal so as to initiate de novo bone induction.
Degenerative bone diseases and bone defects are relatively common and they are debilitating. Perhaps the most common example of one such disease is osteoporosis which tends to affect post-menopausal and hormonally deficient woman, and elderly men. Osteoporosis is a condition manifest in the reduction in the protein and mineral content of bone tissue which results in fragile and porous bones. As a result the bones tend to break easily and they also do not heal as rapidly as healthy bone. In severe conditions a sufferer a may need to have his or her joints replaced at regular intervals. Treatment by replacement hormone therapy can be effective, particularly in woman who are relatively young and have > had an hysterectomy, but such treatment is chronic in that the patient must ingest hormonally preparations for the rest of her life. In addition, hormone replacement therapy may not always be effective. Consequently a composition that initiates de novo formation of healthy bone could be used to treat the majority of such
CONFIRMATION COPY persons and reduce their dependency on chronic hormonal preparations and/or . surgical procedures. ¢ A composition that initiates de novo formation of healthy bone could also be used : in situations where bones are traumatized such as, for example, in a motor vehicle accident, while playing sport or during certain surgical procedures. Such surgical procedures can involve the removal of a portion of the iliac crest of the pelvic bone to graft into a bony defect where it acts as an autogenous bone graft to repair any one of several bone defects in a variety of bones. This technique is widely employed by orthopedic surgeons, surgeons involved in reconstructive surgery and maxillofacial surgeons. Another example involves cosmetic surgery where bones are displaced or deliberately fractured. A third example is provided by certain periodontal procedures which expose the roots and/or dentine of teeth such as in periodontal regenerative surgery and a fourth example is also provided by dental procedures where dental cavities are formed as a result of caries.
The use of bone morphogenetic and osteogenic proteins in inducing de novo formation of bone is well known in medical science. To induce bone formation effectively these proteins should be administered where bone formation is needed in combination or in conjunction with a carrier matrix so as to trigger a bone differentiation cascade. In 2000, direct adenoviral gene therapy was used to produce spinal fusion in rodents. The virus vector was injected directly into the fractured or osteoporotic vertebrae and this resulted in a de novo bone formation at the injection site. This method of stiffening bone formation does have a disadvantage the for its effectiveness in sites having healthy blood flow may be limited for it is conceivable that the vector can be washed out into the peripheral
A circulation before adequate transfection has occurred.
It is generally accepted that bone morphogenetic proteins myst, to be effective,
R be delivered and remain in situ for a sufficient time to trigger the cascade of ’ sequential events that lead to de novo bone induction.
Please note that the term "bone morphogenetic protein” as used in this specification is used, unless the context indicates otherwise, to refer to any one or more of a class of proteins that have been demonstrated to be effective in inducing de novo formation of bone and includes bone morphogenetic proteins, osteogenic proteins, and transformation growth factors — betas. All of which are know to persons skilled in this art as osteogenic members of the TGF-§ superfamily.
Is an object of this invention to provide a composition for stimulating de novo bone induction and to provide a delivery system for initiating de novo bone induction.
In accordance with this invention is provided a composition for stimulating de novo bone induction comprising a combination of a bone morphogenetic protein and a reconstituted basement membrane which is in a gel form at the normal body temperature of the animal to be treated, said composition being introducible into the body of an animal to be treated at a site where the de novo induction of bone is desired, the reconstituted basement membrane serving, at least partly, to retain the bone morphogenetic protein at said site for a period sufficient to trigger
A a bone differentiation cascade. ’ 30 There is further provided for the composition to include an osteogenic protein, alternatively a transformation growth factor-beta and for the bone morphogenetic protein to be selected from the group comprising a recombinant human bone . morphogenetic protein, an osteogenic protein and transformation growth factor { beta.
There is also provided for the reconstituted basement membrane to be a growth factor reduced matrix, for the matrix to predominantly contain laminin, type IV collagen and heparan sulphate proteoglycan, and for the reconstituted basement membrane to be a MATRIGEL® matrix. Alternatively there is provided for the growth factor reduced matrix to be manufactured by combining extra cellular matrix components produced by recombinant DNA technology
There is further provided for the composition to be used to stimulate de novo formation of bone in cases where the animal to be treated has suffered accidental trauma to its bones, alternatively where the animal to be treated has suffered surgical trauma to its bones, further altematively where the animal to be treated is suffering from a degenerative bone disorder such as, for example, osteoporosis and still further preferably a bone defect, and for the animal to be treated to be a mammal, preferably a primate and further preferably a human.
The invention also provides for a method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones, said method comprising introducing, into the body of the mammal to be treated at a site where the de novo induction of bone is desired, a composition for stimulating de novo bone induction comprising a combination of a bone morphogenetic protein and a reconstituted basement membrane which is in a gel form at the normal body temperature of the mammal, the reconstituted basement membrane serving, at least partly, to retain the bone morphogenetic protein at the site of introduction for
K a period sufficient to trigger a bone differentiation cascade. ! 30 There is further provided for the composition to include an osteogenic protein, alternatively a transformation growth factor beta and for the bone morphogenetic protein to be a recombinant human bone morphogenetic protein, osteogenic . protein or transformation growth factor-beta. [3 + There is also provided for the reconstituted basement membrane to be a growth 5 factor reduced matrix, for the matrix to predominantly contain laminin, type IV collagen and heparan sulphate proteoglycan, and for the reconstituted basement membrane to be a MATRIGEL® matrix.
There is further provided for the degenerative bone disorder or trauma from which the mammal is suffering to be skeletal defects, alternatively periodonta defects and, further alternatively, systemic bone loss such as, for example, osteoporosis and for the method to provide for local injection of osteogenic members of the transforming growth factor-beta superfamily to locally treat skeletal defects, non-union fractures and bones affected by systemic bone loss.
The invention also provides for the mammal to be treated to be a primate and, preferably, a human.
~ 20 Embodiments of the invention will be described below by way of example only and with reference to the accompanying examples in which:
Example 1 is a rodent bioassay demonstrating the osteogenic activity and delivery of bone morphogenetic proteins and osteogenic proteins by basement membrane MATRIGEL® ; and,
Example 2 demonstrates a novel method for de novo induction of bone in 4 ovariectomized primates Papio ursinus affected by systemic bone loss. ®
) Example 1 A rodent bioassay demonstrating the osteogenic activity and delivery of bone morphogenetic proteins and osteogenic proteins or t any other human recombinant bone morphogenetic protein and transforming growth factor-beta by basement membrane
MATRIGEL®
To study the osteogenic activity and delivery of bone morphogenetic proteins by basement membrane Matrigel a heterotopic rodent bioassay was selected
Aliquots of the naturally-derived soluble signals, bone morphogenetic proteins (BMP) and osteogenic proteins (OP), were extracted and purified after gel filtration chromatography. Alternatively recombinant human osteogenic protein (hOP-1) could be used. Doses of 2 and 4ug of (hOP-1) were dissolved in 5 mM
HCI and added to basement membrane Matrigel at a concentration of 250 i
Matrigel per dose of soluble signals. Reconstituted stock solutions of basement membrane Matrigel were kept fluid on ice, vortexed and aliquots of 250 ul were recovered using 500 pl pipettes. These aliquots were injected into the subcutaneous space at bilateral sites over the pectoralis fascia of anaesthetized 28 — 35 days-old Long Evans rats.
A total of 14 Long Evans rats were used and implanted with 16 basement membrane Matrigel with 20 pl osteogenic fractions of naturally-derived
BMPs/OPs after gel filtration chromatography and 8 basement membrane
Matrigel to which 2ug and 4pg hOP-1 in 5mM HCI were added. Basement membrane Matrigel, 250pl but without soluble signals was also implanted as control. Skin incisions were closed in one layer using atraumatic 2-0 resorbable sutures. Implants were harvested on day 12 and generated ossicles were fixed in
X ethanol, infiltrated and embedded in Historesin. Sections, cut at 2um, were stained with toluidine blue.
At harvest, basement membrane Matrigel reconstituted with doses of naturally-
N derived BMPs/OPs and hOP-1 resulted in firm and enlarged highly vascularized red ossicles. In all instances, the histological analysis showed a reprodible » pattern of extensive endochondral bone differentiation, vascular invasion and remodelling of the newly formed ossicles. Doses of 4ug hOP-1 induced substantial haemopoietic bone marrow with marked chondrolysis.
Example 2 A novel method for de novo induction of bone in ovariectomized primates Papio ursinus affected by systemic bone loss.
In a cohort of long-term ovariectomized (OVX) primates, Papio ursinus, morphological and structural iliac crest histomorphometric data 36 months post-
OVX showed that bone trabecular morphology was permanently lost after OVX.
Bone mineral density (BMD) measurements of the lumbar spine showed L3 and
L4 more intensely affected by oestrogen depletion than other skeletal areas examined. After the identification of the basement membrane Matrigel as carrier for the osteogenic activity of BMPs/OPs, it was envisaged that the direct injection of naturally-derived BMPs/OPs would initiate bone formation in the affected vertebral bodies with recovery of the original trabecular morphology.
The above study was conducted according to the Guidelines for the Care and
Use of Experimental Animals prepared by the University of the Witwatersrand and in compliance with the National Code for Animal Use in Research, Education and Diagnosis in South Africa. Before any procedures were initiated, research protocols were approved by the Animal Ethics Screening Committee of the
University (Clearance Certificate 2000/35/5). Two adult females weighing 26.2 and 20.7 kg respectively, were selected from the Units’s cohort of 24 OVX primates Papio ursinus. Animals were immobilized and anaestherised and, after surgical preparation of the injection site, a pediatric bone marrow biopsy needle was inserted through the posterior wall of the third and forth vertebral body with the baboon in lateral position, 2-2.5 cm off the midline, 5cm below the superior edge of the spinous process at an angle between 35 and 40° off the midline
N considering the sagittal plane of the vertebra. Growth factors-reduced (Gfr)
Matrigel Matrix was used to absorb and deliver naturally-derived BMPs/OPs ‘ extracted and purified from bovine bone matrix. Total amount injected into each vertebra was 1 ml Gfr-Matrigel and 0.5 ml of 5mM hydrochloric acid containing 500 pg of naturally-derived BMPs/OPs. Animals fully recovered from the experiment and no signs of neurological deficits were noted immediately after experimentation nor during later observation.
On day 0, 30 and 90 bone mineral density (BMD) of selected skeletal sites was measured by dual photon x-ray absorptionmetry (DXA). Lateral (L2,3 and 4) vertebral BMD was measured by the Hologic QDR 4500/A osteodensitometer.
Before lateral BMD measurements, we investigated the anatomy of vertebral body sections from a group of euthanased adult female baboon which were part of different studies. Lumbar vertebral dimension was measured on lateral x-ray of experimental animals and on post-mortem specimens of adult female baboons lumbar vertebrae obtained from different experiments. Areas of L1,2,3 and 4 were measured and data were used to analyse lateral BMD images. Only the central areas of the vertebra was analysed on the later image, allowing a reproducible analysis of the cancellous bone. The transverse axis was similar in all four vertebrae while the longitudinal axis was longer in L3 and L4 (Table 1) and the region of interest area (ROI) was also greater in L3 and L4 (Table 2). L2 was not injected. Baboon 1, L2 showed a decreased BMD (-6.1%) 30 days after the local injection followed by a gain (9.3%) on day 90. Baboon 2, L2 showed a steady BMD on day 30 and a positive gain (10.3%) on day 90. L3 of animal 1 showed a rapid bone loss (-23%) after injection which was followed by a rapid bone gain (38%) as measured 90 days after injection. Compared to baseline, L3 § BMD 90 days after injection was 20% higher. Animal 2 showed a rapid bone loss in L3 (-9.4%) and only a minimal trend of recovery (0.9%) during 90 days ’ 30 observation. L4 of animal 1 BMD was markedly increased 30 days post-injection (41%) but this was followed by 60 days of rapid bone loss (-49%) which resulted -
in a net 13.7% negative difference compared to baseline. Animal 2 L$ BMD 3 showed a steady increase during observations, 8.3% and 11.7% at 30 and 90 days respectively.
Although only four vertebrae in two animals were injected, results showed that bone remodelling has changed in the treated lumbar vertebrae and the trend of bone loss on day 30 after injection in L3 was followed by a period of rapid recovery detected 2 months later. This may be the result of rapid remodelling followed by bone formation by induction. At this stage it may be premature to formulate mechanistic hypotheses on bone behaviour for these non linear trend, nevertheless these changes were important and promptly detected by lateral
BMD measurements. Although L2 was not injected, an increased BMD in both animals were detected on day 90. It is likely that events in nearby vertebrae propagated signals to initiate bone formation to untreated bones through the circulatory system. Although we were not able to follow the distribution of reconstituted basement membrane Matrigel within the injected vertebral bodies nor the time of exposure of BMPs/OPs with responding cells it is, nevertheless, believed that this therapeutic approach, particularly the direct injection of : basement membrane Matrigel reconstituted with BMPs/OPs acting as a novel soluble delivery system is an innovative approach for the treatment of established osteoporosis in clinical contexts as well as a novel delivery system for BMPs/OPs and transforming growth factor betas to initiate bone formation by induction in a variety of skeletal defects.
It will be appreciated that, while example relates to a method of de novo bone induction in primates, the techniques described can be extended the induction of de novo bone formation in humans. f
Claims (26)
1. A composition for stimulating de novo bone induction comprising a combination of a bone morphogenetic protein and a reconstituted bd basement membrane which is in a gel form at the normal body 5 temperature of an animal to be treated, said composition being ~~ introducible into the body of an animal to be treated at a site where the de novo induction of bone is desired, the reconstituted basement membrane serving, at least partly, to retain the bone morphogenetic protein at said site for a period sufficient to trigger a bone differentiation cascade.
2. A composition for stimulating de novo bone induction as claimed in claim 1 which includes an osteogenic protein.
3. A composition for stimulating de novo bone induction as claimed in claim 1 which includes a transformation growth factor.
4. A composition for stimulating de novo bone induction as claimed in any one of the preceding claims in which the bone morphogenetic protein is selected from the group comprising a recombinant human bone morphogenetic protein, an osteogenic protein and transformation growth factor beta.
5. A composition for stimulating de novo bone induction as claimed in any one of the preceding claims in which the reconstituted basement membrane is a growth factor reduced matrix.
6. A composition for stimulating de novo bone induction as claimed in claim 5 in which the growth factor reduced matrix predominantly contains laminin, type IV collagen and heparan sulphate proteoglycan.
7. A composition for stimulating de novo bone induction as claimed in claim 5 in which the reconstituted basement membrane is a MATRIGEL® matrix.
J 8. A composition for stimulating de novo bone induction as claimed in claim 5 5 in which the reconstituted basement membrane is manufactured by combining extra cellular matrix components produced by recombinant DNA technology.
9. A composition for stimulating de novo bone induction as claimed in any one of the preceding claims in which the animal to be treated is a mammal.
10. A composition for stimulating de novo bone induction as claimed in claim 9 in which the mammal is a primate.
11. A composition for stimulating de novo bone induction as claimed in claim 10 in which the primate is a human.
12. Use of a composition for stimulating de novo bone induction as claimed in any one of the preceding claims to stimulate de novo formation of bone in “an animal that has suffered accidental trauma to its bones comprising introducing said composition into the body of the animal at or close to the site of trauma.
13. Use of a composition for stimulating de novo bone induction as claimed in any one of claims 1 to 11 to stimulate de novo formation of bone in an animal that has suffered surgical trauma to its bones comprising introducing said composition into the body of the animal at or close to the site of trauma.
14. Use of a composition for stimulating de novo bone induction as claimed in any one of claims 1 to 11 to stimulate de novo formation of bone in an animal that is suffering from a degenerative bone disorder such as, for ~ example, osteoporosis comprising introducing said composition into the body of the animal at or close to the site of bone suffering from said degenerative bone disorder.
15. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones, said method comprising introducing, into the body of the mammal to be treated at a site where the de novo induction of bone is desired, a composition for stimulating de novo bone induction comprising a combination of a bone morphogenetic protein and a reconstituted basement membrane which is in a gel form at the normal body temperature of the mammal, the reconstituted basement membrane serving, at least partly, to retain the bone morphogenetic protein at the site of introduction for a period sufficient to trigger a bone differentiation cascade.
16. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in claim 15 in which the composition for stimulating de novo bone induction includes an osteogenic protein.
17. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in claim 15 in which the composition for stimulating de novo bone induction includes a transformation growth factor beta.
18. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in claim 15 in which the bong morphogenetic protein component of said composition is selected from the group comprising a recombinant human bone morphogenetic protein, an osteogenic protein and transformation growth factor beta. .
19. A method of treating a mammal suffering from a degenerative bone 5 disorder or trauma to its bones as claimed in any one claims15 to 18 in which the reconstituted basement membrane component of the composition is a growth factor reduced matrix.
20. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in claim 19.in which the matrix predominantly contains laminin, type IV collagen and heparan sulphate proteoglycan.
21. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in any one claims 15 to 18 in which the reconstituted basement membrane component of the composition is a MATRIGEL® matrix.
22. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in any one claims 15 to 21 in which the degenerative bone disorder or trauma from which the mammal is suffering are skeletal defects.
23. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in any one claims 15 to 21 in which the degenerative bone disorder or trauma from which the mammal is suffering are periodontal defects. Y
24. A method of treating a mammal suffering from a degenerative bone ’ 30 disorder or trauma to its bones as claimed in any one claims 15 to 21 in which the degenerative bone disorder or trauma from which the mammal é é 14 is suffering are caused by systemic bone loss such as, for example, ® osteoporosis. hd
25. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in any one claims 15 to 24 in which the method to osteogenic members of the transforming growth factor-beta superfamily are injectedn locally to locally treat skeletal defects, non-union fractures and bones affected by systemic bone loss..
26. A method of treating a mammal suffering from a degenerative bone disorder or trauma to its bones as claimed in any one of claims 15 to 25 in which the reconstituted basement membrane is a product of a combination of extra cellular matrix components produced by recombinant DNA technology. 14
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200202307 | 2002-03-22 | ||
PCT/IB2003/001021 WO2003079964A2 (en) | 2002-03-22 | 2003-03-20 | Composition for stimulating de novo bone induction |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200408571B true ZA200408571B (en) | 2005-08-31 |
Family
ID=28455332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2004/08571A ZA200408571B (en) | 2002-03-22 | 2004-10-22 | Composition for stimulating de novo bone induction |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1494702A4 (en) |
AU (1) | AU2003212562A1 (en) |
WO (1) | WO2003079964A2 (en) |
ZA (1) | ZA200408571B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1279973C (en) * | 2004-07-22 | 2006-10-18 | 徐放 | Injected gel type bone repairing biological active material and its preparing method |
EP1948218B1 (en) | 2005-10-17 | 2015-04-15 | University of the Witwatersrand, Johannesburg | Osteogenic device for inducing bone formation in clinical contexts |
WO2011154882A1 (en) * | 2010-06-06 | 2011-12-15 | University Of The Witwatersrand, Johannesburg | Induction of bone formation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5508188A (en) * | 1994-01-21 | 1996-04-16 | The Regents Of The University Of California | Method of growing cells in a mammal |
EP0907721A1 (en) * | 1996-05-28 | 1999-04-14 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
JP4222726B2 (en) * | 1997-12-02 | 2009-02-12 | ゼン‐バイオ,インコーポレイテッド | Generation and use of osteoblasts |
JP2002520068A (en) * | 1998-07-15 | 2002-07-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Bone morphogenetic protein |
-
2003
- 2003-03-20 WO PCT/IB2003/001021 patent/WO2003079964A2/en not_active Application Discontinuation
- 2003-03-20 AU AU2003212562A patent/AU2003212562A1/en not_active Abandoned
- 2003-03-20 EP EP03708384A patent/EP1494702A4/en not_active Withdrawn
-
2004
- 2004-10-22 ZA ZA2004/08571A patent/ZA200408571B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003212562A1 (en) | 2003-10-08 |
EP1494702A4 (en) | 2009-10-21 |
WO2003079964A3 (en) | 2004-07-29 |
AU2003212562A8 (en) | 2003-10-08 |
WO2003079964A2 (en) | 2003-10-02 |
EP1494702A2 (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boden et al. | Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage | |
Den Boer et al. | Effect of recombinant human osteogenic protein-1 on the healing of a freshly closed diaphyseal fracture | |
Pannier | Congenital pseudarthrosis of the tibia | |
Schell et al. | Osteoclastic activity begins early and increases over the course of bone healing | |
JP3191937B2 (en) | Osteoinductive pharmaceutical preparation | |
Kanakaris et al. | Application of bone morphogenetic proteins to femoral non-unions: a 4-year multicentre experience | |
ES2443581T3 (en) | Compositions and methods for bone treatment | |
EP1988940A1 (en) | Cohesive osteogenic putty and materials therefor | |
US20140106447A1 (en) | Compositions and methods for recruiting stem cells | |
CN110612129B (en) | Autologous bone graft substitute | |
McCarthy | Genetic diseases of bones and joints | |
KR20110100269A (en) | Bone grafts with reduced protease activity and methods of selection and use | |
Zhang et al. | Bone regeneration after radiotherapy in an animal model | |
Jiang et al. | The effects of hypoxia-inducible factor (HIF)-1α protein on bone regeneration during distraction osteogenesis: an animal study | |
Yonezawa et al. | Effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on bone consolidation on distraction osteogenesis: a preliminary study in rabbit mandibles | |
US20060052304A1 (en) | Method for remodeling bone and related sutures | |
WO1998031788A1 (en) | Injectable formulations for treatment of osteoporotic bone | |
ZA200408571B (en) | Composition for stimulating de novo bone induction | |
Lin et al. | Post-traumatic fronto-ethmoid osteomyelitis treated with free muscle transfer | |
Newsom et al. | Design and evaluation of 3D-printed Sr-HT-Gahnite bioceramic for FDA regulatory submission: A Good Laboratory Practice sheep study | |
US20050153883A1 (en) | Composition for stimulating de novo bone induction | |
Wahl et al. | Direct bone formation during distraction osteogenesis does not require TNFα receptors and elevated serum TNFα fails to inhibit bone formation in TNFR1 deficient mice | |
Ripamonti et al. | Local delivery of bone morphogenetic proteins in primates using a reconstituted basement membrane gel: tissue engineering with Matrigel: research in action | |
Love et al. | Mesenchymal stem cells enhance targeted bone growth from injectable hydrogels with BMP‐2 peptides | |
EP3145514B1 (en) | Formulation for regeneration of bone and cartilage |